This is a preview of subscription content, log in via an institution to check access.
Notes
EU5 Physician & Payer Forum
Reference
Decision Resources. Cost-Constrained Payers Across the EU5 Welcome the Launch of Biosimilars in the RA Market and Anticipate Encouraging or Imposing the Prescription of These Agents to Control the Spending of High-Cost Biologics. Media Release : 3 Sep 2015. Available from: URL: http://www.decisionresourcesgroup.com
Rights and permissions
About this article
Cite this article
RA biosimilars anticipated to combat high-cost biologicals. PharmacoEcon Outcomes News 737, 34 (2015). https://doi.org/10.1007/s40274-015-2480-4
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-015-2480-4